23andMe, the genetics testing company, is in a state of constant evolution, as you’d expect any 12-year-old company would be. But that also means that customers need to be aware of how the company is using data that users may have earlier consented to give without anticipating its newer initiatives. One new tie-up was a … Continue reading 23andMe underscores that privacy-loving customers need to opt out of its data deal with GlaxoSmithKline